Aucta debuts generic Vimpat

Aucta Pharmaceuticals is introducing Motpoly XR (lacosamide) extended-release capsules C-V, in dosage strengths of 100, 150 and 200 mg, which is the generic of Harris FRC’s Vimpat film-coated tablets, C-V. Aucta's product provides a new once-daily option at equivalent doses.

Motpoly XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

[Read more: Aucta receives FDA OK for generic Perforomist]

"Motpoly XR marks a major milestone for Aucta as our first branded pharmaceutical product to enter the U.S. market. It will be supported by a full commercial infrastructure including field and inside sales, managed care and formulary access support and a copay savings program," said Shoufeng Li, CEO of Aucta Pharmaceuticals.